Barrow Robert 4

What Happened Robert Barrow, CEO of Definium Therapeutics (DFTX), reported the sale of 24,431 common shares on March 25, 2026. The weighted-average sale price was $18.47 per share, resulting in proceeds of approximately $451,241. This was a sale (not a purchase) carried out to satisfy tax withholding obligations related to vested restricted stock units.

Key Details

• Transaction date: March 25, 2026 (Form 4 filed March 26, 2026 — timely filing).
• Transaction type: Sale (sell-to-cover to satisfy tax withholding on vested RSUs) under a Rule 10b5-1 plan adopted June 15, 2022.
• Price: Weighted-average $18.47; individual sales ranged from $18.36 to $18.80. The filer will provide a breakdown of shares sold at each price on request.
• Shares sold: 24,431; proceeds ≈ $451,241.
• Shares owned after transaction: Not reported in this filing.
• Footnotes: F1 — sale to satisfy withholding on vested RSUs via sell-to-cover under a 10b5-1 plan; F2 — weighted-average price and range disclosure; F3 — form notes 1,586 shares were acquired under the 2024 Employee Share Purchase Plan.

Context This sale appears to be a routine sell-to-cover for tax withholding on vested RSUs rather than an open-market liquidation motivated by trading views. Such withholding sales are common and do not necessarily indicate the insider’s sentiment about the company’s prospects. Purchases by insiders generally carry more interpretive weight for bullish signals.